CTI BioPharma shares halted premarket for the news

1 News Net

1 News - 1 Movies - 1 Music - 1 eBooks - 1 Search

 

CTI BioPharma says trial of treatment for non-Hodgkin lymphoma failed to meet main goals

CTI BioPharma Corp. said Monday a late-stage trial of a treatment for the blood cancer non-Hodgkin lymphoma failed to meet its main goals. The Phase III trial evaluating Pixuvri combined with rituximab in comparison to gemcitabine combined with rituximab in patients with aggressive B-cell non-Hodgkin lymphoma did not meet its primary endpoint of an improvement in progression-free survival, the company said in a statement. “We are disappointed with the outcome of the PIX306 trial and will proceed to conduct a thorough review of clinical data to assess the next steps for the PIXUVRI program,” Chief Executive Adam Craig, MD, PhD said in a statement. The trial involved 312 patients who had relapsed and were not eligible for stem cell transplant. Shares were halted premarket for the news, but have gained 94% in 2018, while the S&P 500 has gained 3%.

1 News Net

1 News - 1 Movies - 1 Music - 1 eBooks - 1 Search

 

Leave a Reply